Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for MRG003 in recurrent or metastatic nasopharyngeal carcinoma. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• MRG003

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING